Answers are grounded in this paper and cite their sources.
Background Urothelial carcinoma with neuroendocrine differentiation is a rare, yet highly aggressive histological subtype of bladder cancer, characterized by rapid disease progression, poor prognosis, and a tendency to metastasize, with the liver being a common metastatic site. Current treatments involving chemotherapy and immunotherapy have limitations, including poor patient tolerability and the rapid development of drug resistance, particularly in patients exhibiting low PD-L1 expression and those who have failed multiple lines of therapy. Increasing evidence supports the use of low-dose radiotherapy (LDRT) as an immunomodulatory approach that can overcome drug resistance in many patients. Case presentation Herein, we report the case of a 54-year-old male patient with urothelial carcinoma exhibiting partial neuroendocrine differentiation and extensive liver metastases. PD-L1 testing revealed a combined positive score of 1. The patient had developed resistance following first-line chemotherapy and second-line chemoimmunotherapy. As a third-line treatment, he received whole-liver LDRT (WL-LDRT: 5 Gy in 10 fractions), with a simultaneous integrated boost to selected lesions, combined with immunotherapy and chemotherapy. One month post-treatment, imaging demonstrated that the patient had shown a partial response to treatment, athree months later, all the liver metastases were disappeared. Notably, the patient achieved progression-free survival exceeding 9 months. Conclusion To the best of our knowledge, this is the first case report of a patient with extensive liver metastases from bladder cancer who achieved complete radiological response of the hepatic metastases after overcoming resistance to both chemotherapy and immunotherapy with a combination of WL-LDRT and simultaneous integrated boost. This case highlights a novel and potentially safe salvage strategy for treating similar cases of chemotherapy- and immunotherapy-refractory metastatic bladder cancer, which could help improve the clinical outcomes of patients with this rare but highly aggressive cancer.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: